Northwest vs Feuerstein rhubarb round 3

Northwest Biotherapeutics (NWBO -9.9%) takes predictable exception to The Street's Adam Feuerstein regarding his bearish comments after CEO Linda Powers' DCVax presentation on March 27.

The company insists that the statistical significance of the phase 3 trial results increases its chances of success not decreases as Mr. Feuerstein asserts.

It also disputes his opinion that the trial has been poorly run.

For those of you late to the theater, here is some background.

From other sites
Comments (12)
  • mitrado
    , contributor
    Comments (2033) | Send Message
    There's nothing I need to know... I've learnt my lesson with $AMRN and $SPPI. If Adam F. is talking about it, better sell it and move to another stock.
    28 Mar 2014, 01:45 PM Reply Like
  • InmanRoshi
    , contributor
    Comments (217) | Send Message
    I learned my lesson from $KERX that this guy just regurgitates what a big cap product competitors feed him to sabotage upstart competition.

    28 Mar 2014, 05:04 PM Reply Like
  • Houdini10
    , contributor
    Comments (75) | Send Message
    It's becoming pretty clear that Adam's misleading, nonfactual take downs are borderline criminal. Just need to find out who is profiting off his BS.
    28 Mar 2014, 02:22 PM Reply Like
  • tinsley09
    , contributor
    Comments (339) | Send Message
    His(A.F.) headline yesterday was a GROSS distortion of the facts presented at the prestigious New York Academy of Sciences( Academy of Medicine ) meeting..This is one of the oldest science-academic societies in the U.S.A.His comments on elementary statistical analysis(p=0.02 vs p=0.05) DOCUMENTS now in print., his need to retake an undergraduate stat 101 course and get a passing grade ,before he is ever allowed to comment on the methodology of ANY current or FUTURE clinical trial.Unfortunately the majority of readers are innocent of even an undergraduate education in stat.and gullible enough to trust sound bites and headlines ,WITHOUT checking out the PRIMARY sources.
    28 Mar 2014, 04:07 PM Reply Like
  • Navy
    , contributor
    Comments (289) | Send Message
    My info says his background is political science not biotech. So why give him the benefit of the doubt over some scientists who are betting their own money?
    28 Mar 2014, 04:09 PM Reply Like
  • InmanRoshi
    , contributor
    Comments (217) | Send Message
    You got to hand it to him. It's a credit to his ability to self promote that a person with no background in hard science writing for a 3rd rate publication gets such attention.
    28 Mar 2014, 04:45 PM Reply Like
  • Relayer
    , contributor
    Comments (38) | Send Message
    I haven't done do any real DD on this (disclaimer), but I would bet that if one simply bought on the lows each time Adam wrote an article on NWBO, one would have profited nicely. I'm averaged in at well below $4 and am long this very promising technology. Adam is doing all the believers a favor by providing predictable buy opportunities. Nice work!
    28 Mar 2014, 04:11 PM Reply Like
  • lgilham
    , contributor
    Comments (30) | Send Message
    Are you saying he knows what the outcomes of the trials are or there is a history of manipulating BIOTECH firms? If either case is correct, it doesn't bode well for this promising stock.
    30 Mar 2014, 02:40 AM Reply Like
  • libouban
    , contributor
    Comments (143) | Send Message
    Rhubarb round? Is that how you title the refutation of claims which attack the reputation of a biotech company and the CEO?
    Late to the theater? What a cynical view of advances in health and science.
    S.A. wrote a number of articles about how to improve their editorial policy. This is not the policy which was announced.
    30 Mar 2014, 02:41 AM Reply Like
  • tinsley09
    , contributor
    Comments (339) | Send Message
    This level of IMPLICIT cynical comment is profoundly depressing for an outlet that was recently POSITIVELY cited in an academic journal.What about scientific objectivity and integrity.?
    30 Mar 2014, 09:25 AM Reply Like
    , contributor
    Comments (2) | Send Message
    Has anyone ever heard Feuerstein say something positive about any bio stock? This is a man who has zero knowledge of the science or the industry attempting to manipulate the value of a stock for his own entertainment........and probably to make a few bucks on the short side. I think he should go back to selling software.
    30 Mar 2014, 02:42 AM Reply Like
  • tinsley09
    , contributor
    Comments (339) | Send Message
    A.F will repeat his "FALSE AND MISLEADING CLAIMS"(NWBO Newswire3 /27/2014) when the ASCO report in May 2014 is issued by it's authors ,Vivek Subbiah et al (MD Anderson Cancer Center).He has consistently DISTORTED ALL THREE prior reports( 1.the DMC report,2.the positive German FDA report on hospital exemption,3.Linda Powers report to the prestigious New York Academy of Medicine(New York Academy of Sciences) and there is a high probability he will repeat his distortions in May 2014.IT will be MUCH easier to distort the ASCO report because it will written in the technical language of science and statistics .The bulk of retail investors in DCVAX-L and Direct are probably innocent of any education in stat.and science . Multiple converging complaints to the SEC about these systematic DISTORTIONS may have some efficacy.
    30 Mar 2014, 09:14 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs